No retraction, correction or concern found when last checked on Oct 21, 2026.
Recent advances in understanding and managing male infertility
Jonathan Fainberg, James A. Kashanian
F1000Research · 2019 · Review
doi:10.12688/f1000research.17076.1
Abstract
Infertility is a prevalent condition affecting an estimated 70 million people globally. The World Health Organization estimates that 9% of couples worldwide struggle with fertility issues and that male factor contributes to 50% of the issues. Male infertility has a variety of causes, ranging from genetic mutations to lifestyle choices to medical illnesses or medications. Recent studies examining DNA fragmentation, capacitation, and advanced paternal age have shed light on previously unknown topics. The role of conventional male reproductive surgeries aimed at improving or addressing male factor infertility, such as varicocelectomy and testicular sperm extraction, have recently been studied in an attempt to expand their narrow indications. Despite advances in the understanding of male infertility, idiopathic sperm abnormalities still account for about 30% of male infertility. With current and future efforts examining the molecular and genetic factors responsible for spermatogenesis and fertilization, we may be better able to understand etiologies of male factor infertility and thus improve outcomes for our patients.
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.
Introduction
Infertility is a prevalent condition affecting an estimated 70 million people globally. The World Health Organization (WHO) estimates that 9% of couples worldwide struggle with fertility issues and that male factor contributes to 50% of the issues. Many genetic and lifestyle factors have been implicated in male infertility; however, about 30% of cases are still thought to be idiopathic. Recent advances in sperm DNA fragmentation, capacitation, and nanotechnology have shed light on these enigmatic causes. Here, we will discuss the epidemiology, causes, and recent advances in the understanding and management of male factor infertility.
Discussion/analysis of the recent literature
Infertility is a condition that is well recognized by the WHO. Although worldwide prevalence data are lacking, couple infertility is estimated to affect 72.4 million people globally, according to large population surveys. Additionally, the WHO estimates that 9% of couples worldwide struggle with fertility issues and that the male factor accounts for 50% of couple sub-fertility. More recent US data gathered during interviews from 22,682 men and women who are 15 to 44 years old suggest that as many as 12% of men are sub-fertile.
Male infertility has a variety of causes, ranging from genetic mutations to lifestyle choices to medical illnesses or medications. Despite advances in the understanding of male infertility, idiopathic sperm abnormalities still account for about 30% of male infertility. Nonetheless, a variety of medical comorbid conditions have been found to affect semen parameters. To name a few, these include renal disease, liver failure, hemochromatosis, chronic obstructive pulmonary disease, cystic fibrosis, and multiple sclerosis. An Italian study of 2,100 consecutive infertile men examined the relationship between Charlson Comorbidity Index (CCI), semen parameters, and hormonal levels. The study demonstrated that, with an increasing CCI (a marker of poor health), semen parameters deteriorate and follicle-stimulating hormone (FSH) levels rise, suggestive of pituitary compensation in the setting of spermatogenic dysfunction. The mechanism by which medical conditions may impact fertility includes effects on hormonal levels, impairment of sexual function (including ejaculatory function), or impairment of testicular function/spermatogenesis. By medically optimizing a man’s health, improvements in medical disease status can improve semen parameters, sexual function, and fertility potential.
For instance, obesity is associated with male infertility, likely because of hormonal changes secondary to excess adipose tissue. In a retrospective multi-institutional cohort study, Bieniek et al. demonstrated an inverse relationship between body mass index (BMI) and testosterone, testosterone-to-estradiol ratio, ejaculate volume, sperm concentration, and morphology. The authors also reported higher rates of azoospermia and oligospermia among obese men (12.7% and 31.7%, respectively) compared with men of normal weight (9.8% and 24.5%). Additionally, couples made up of an overweight or obese man with a female partner of normal BMI have increased time to conceive compared with couples with male partners of normal weight. Couples undergoing assisted reproductive technology (ART), in which the male partner is obese, also have decreased pregnancy rates and increased pregnancy loss, possibly due to higher DNA fragmentation rates in obese men,.
Similarly, studies suggest that male infertility may be an early sign of poor overall health. Not only may infertility be the presenting sign of an underlying medical condition, but men with abnormal semen parameters may be at a higher risk of malignancy. Testicular cancer risk increases up to 20-fold in men with abnormal semen parameters. This risk even translates to first-degree relatives of men with abnormal semen analyses,. It has also been suggested that male infertility may be related to an increased risk of prostate cancer. Additionally, when examining claims data for over 76,000 infertile men in the US, investigators found a 49% increased risk of a broad range of cancers compared with controls. One study found that azoospermic men have a threefold increased risk of all cancers, suggesting that there is a possible shared etiology between azoospermia and cancer development. Other recent studies have touted the semen analysis as a barometer for overall men’s health, correlating decreasing semen parameters with increased male morbidity and mortality.
Levine et al., in 2017, published a study demonstrating declining sperm concentrations in the US and worldwide. The etiologies behind these findings of decreasing sperm counts are difficult to pinpoint but may be due in part to increasing rates of overweight and obese men of childbearing age. Additionally, pesticide exposure and illicit drug and tobacco use could be implicated as well, although no causal relationship between these behaviors and decreased sperm parameters currently exists. In recent years, at-home sperm analysis kits have become widely commercially available, allowing men to do a cursory test of their fertility. Most products provide binary (yes/no) results for sperm concentration on the basis of WHO-recommended cutoff values of either 15 or 20 M/mL. These provide low-cost and accessible options for diagnosis for men who previously may have forgone medical care.
Advanced maternal age has long been known to negatively influence fertility. In many countries, the average age of paternity is rising and increasing reports demonstrate that advanced age similarly affects male fertility. Contemporary evidence confirms that older men have worse semen parameters, poorer reproductive outcomes with unassisted pregnancy, and an increased risk of health problems in their offspring. Specifically, data show that the offspring of older men have an increased risk of neuropsychiatric conditions. Data on the offspring of older fathers, including IQ scores, social skills, and a variety of other health outcomes, are conflicting and need to be studied in greater depth.
Another recognized cause of male infertility relates to unintended impacts due to medications. Young men may require medications that can decrease fertility and alter the hypogonadal–pituitary–gonadal axis. These medications include chemotherapeutic agents, psychotropic medications, long-term cortico-steroid use, calcium-channel blockers, alpha-blockers, 5-alpha reductase inhibitors (for androgenic alopecia/male pattern baldness), or testosterone replacement therapy. Frequently, these medications are prescribed without a conversation regarding possible effects on current or future fertility. These medications can alter semen parameters, decrease spermatogenesis, or lead to increased sexual and ejaculatory dysfunction. It is of the utmost importance to fully review all past, present, and potential future medications in men actively considering conception and those interested in future fertility.
The role of conventional male reproductive surgeries aimed at improving or addressing male factor infertility has recently been studied in an attempt to expand their narrow indications. These surgeries include varicocelectomy and testicular sperm extraction (TESE). Varicoceles, the abnormally dilated and tortuous veins in the pampiniform plexus, are a common cause of male infertility. Varicoceles are present in an estimated 15 to 20% of the general male population and 35 to 40% of infertile men. The mechanism of action by which a varicocele affects fertility is thought to be related primarily to blood stasis in the scrotum, creating excess heat, which in turn reduces spermatogenesis. However, there are additional theories of how a varicocele can negatively affect fertility, including metabolite reflux into the testis and increased reactive oxygen species creating sperm DNA damage and hormonal dysregulation. Varicocelectomy has been shown to improve semen parameters, as demonstrated in a 2011 meta-analysis, which found improvement in sperm concentration as well as total and progressive motility following varicocele repair. Typically, semen parameters will improve by 3 to 6 months after repair. Another meta-analysis, from 2016, confirmed that repairing varicoceles prior to ARTs improves pregnancy and live birth rates in oligospermic and azoospermic men. One recent study of men with non-obstructive azoospermia (NOA) showed an increased return of sperm to the ejaculate following varicocele repair and higher rates of live births when compared with controls with NOA and no varicocele. Similarly, a 2016 meta-analysis concluded that varicocelectomy in men with NOA and clinical varicocele improved surgical sperm recovery rates. In 2012, Mansour Ghanaie et al. published a randomized control trial examining varicocele repair in couples with recurrent first-trimester miscarriages. They showed that varicocelectomy significantly improved semen parameters but interestingly also increased pregnancy rates and decreased miscarriage rates significantly.
TESE has historically been used only for men who have azoospermia. Recently, men with severe oligospermia (sperm concentration below 5 million sperm per milliliter), cryptozoospermia (viable sperm found only under conventional microscopy of centrifuged semen samples), or sperm with high DNA fragmentation rates have been shown to potentially benefit from TESE. In 2017, Cui et al. demonstrated that testicular sperm were superior to ejaculated sperm in men with cryptozoospermia undergoing intracytoplasmic sperm injection (ICSI); pregnancy rates were 53.6% in the TESE group and 33.3% in the ejaculated sperm group. However, a 2016 meta-analysis did not support these findings. Another meta-analysis did show that testicular sperm had lower DNA fragmentation rates than ejaculated sperm and that using ICSI had higher clinical pregnancy and live birth rates. Further studies are warranted in order to corroborate these results.
Sperm DNA fragmentation is a novel and potentially valuable tool for male fertility evaluation. Increased sperm DNA fragmentation is known to negatively impact pregnancy rates. Recently, there has been some controversy over the utility of DNA fragmentation tests in predicting ART outcomes. Owing to the lack of standardization among the tests and the inability in smaller studies to predict outcomes, prior guidelines had cautioned practitioners in testing for sperm DNA damage. However, Simon et al. recently published a systematic review and meta-analysis concluding that DNA damage has a negative effect on clinical pregnancy rates following both in vitro fertilization and ICSI. Newer guidelines based on up-to-date evidence regarding these DNA fragmentation tests are now available.
Given the data on DNA fragmentation, many studies have attempted to identify efficient and effective means of sperm cell sorting to identify the undamaged sperm and selectively use these for ART. Magnetic activated, flow cytometric, and microfluidic sperm sorting are examples of techniques for identifying semen samples with viable sperm low DNA fragmentation indexes –. These techniques have limitations, and research investigating whether nanotechnology can aide in sperm sorting is under way.
An area that has recently regained attention is capacitation, the functional maturation of sperm that takes place in vivo along the female reproductive tract. As sperm progress toward the egg, sperm respond to stimuli and undergo molecular reactions that prepare them for fertilization. Defects in capacitation impair the fertilizing capability of sperm. The Cap-Score™ is an investigational test that measures sperm capacitation potential. Other diagnostic tests, such as MiOXSYS, which measures oxidative stress, have also gained interest recently. Further development of novel semen and sperm tests will aid in providing more dynamic information than the standard semen analysis.
Conclusions
Infertility is a prevalent condition that affects over 70 million people globally. A variety of lifestyle choices and genetic issues have been implicated in the condition. While poor overall health contributes to infertility, it has also been demonstrated that infertility is associated with an increased risk of a variety of malignancies. Recent studies examining DNA fragmentation, capacitation, and advanced paternal age have shed light on previously unknown topics. Despite recent advances, about one third of cases remain idiopathic. With current and future efforts examining the molecular and genetic factors responsible for spermatogenesis and fertilization, we may be better able to understand etiologies of male factor infertility and thus improve outcomes for our patients.
References 46
- 1.
Boivin J Bunting L Collins JA: International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod. 2007;22(6):1506–12.
Not in our library10.1093/humrep/dem046
- 2.
World Health Organization: Towards more objectivity in diagnosis and management of male fertility. Int J Androl. 1987;7:1–53. Reference Source
Not in our library
- 3.
Cavallini G: Male idiopathic oligoasthenoteratozoospermia. Asian J Androl. 2006;8(2):143–57.
Not in our library10.1111/j.1745-7262.2006.00123.x
- 4.
Ventimiglia E Capogrosso P Boeri L: Infertility as a proxy of general male health: results of a cross-sectional survey. Fertil Steril. 2015;104(1):48–55.
Not in our library10.1016/j.fertnstert.2015.04.020
- 5.
Lotti F Maggi M: Sexual dysfunction and male infertility. Nat Rev Urol. 2018;15(5):287–307.
Not in our library10.1038/nrurol.2018.20
- 6.
Bieniek JM Kashanian JA Deibert CM: Influence of increasing body mass index on semen and reproductive hormonal parameters in a multi-institutional cohort of subfertile men. Fertil Steril. 2016;106(5):1070–5.
Not in our library10.1016/j.fertnstert.2016.06.041
- 7.
Campbell JM Lane M Owens JA: Paternal obesity negatively affects male fertility and assisted reproduction outcomes: a systematic review and meta-analysis. Reprod Biomed Online. 2015;31(5):593–604.
Not in our library10.1016/j.rbmo.2015.07.012
- 8.
Bakos HW Henshaw RC Mitchell M: Paternal body mass index is associated with decreased blastocyst development and reduced live birth rates following assisted reproductive technology. Fertil Steril. 2011;95(5):1700–4.
Not in our library10.1016/j.fertnstert.2010.11.044
- 9.
Dupont C Faure C Sermondade N: Obesity leads to higher risk of sperm DNA damage in infertile patients. Asian J Androl. 2013;15(5):622–5.
Not in our library10.1038/aja.2013.65
- 10.
Raman JD Nobert CF Goldstein M: Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. J Urol. 2005;174(5):1819–22; discussion 1822.
Not in our library10.1097/01.ju.0000177491.98461.aa
- 11.
Anderson RE Hanson HA Patel DP: Cancer risk in first- and second-degree relatives of men with poor semen quality. Fertil Steril. 2016;106(3):731–8.
Not in our library10.1016/j.fertnstert.2016.05.021
- 12.
Hanson HA Anderson RE Aston KI: Subfertility increases risk of testicular cancer: evidence from population-based semen samples. Fertil Steril. 2016;105(2):322–328.e1.
Not in our library10.1016/j.fertnstert.2015.10.027
- 13.
Walsh TJ: Male reproductive health and prostate cancer risk. Curr Opin Urol. 2011;21(6):506–13.
Not in our library10.1097/mou.0b013e32834bdf14
- 14.
Eisenberg ML Li S Brooks JD: Increased risk of cancer in infertile men: analysis of U.S. claims data. J Urol. 2015;193(5):1596–601.
Not in our library10.1016/j.juro.2014.11.080
- 15.
Eisenberg ML Betts P Herder D: Increased risk of cancer among azoospermic men. Fertil Steril. 2013;100(3):681–5.
Not in our library10.1016/j.fertnstert.2013.05.022
- 16.
Eisenberg ML Li S Cullen MR: Increased risk of incident chronic medical conditions in infertile men: analysis of United States claims data. Fertil Steril. 2016;105(3):629–36.
Not in our library10.1016/j.fertnstert.2015.11.011
- 17.
Levine H Jørgensen N Martino-Andrade A: Temporal trends in sperm count: a systematic review and meta-regression analysis. Hum Reprod Update. 2017;23(6):646–59.
Not in our library10.1093/humupd/dmx022
- 18.
Yu S Rubin M Geevarughese S: Emerging technologies for home-based semen analysis. Andrology. 2018;6(1):10–9.
Not in our library10.1111/andr.12441
- 19.
Mazur DJ Lipshultz LI: Infertility in the Aging Male. Curr Urol Rep. 2018;19(7):54.
Not in our library10.1007/s11934-018-0802-3
- 20.
Samplaski MK Nangia AK: Adverse effects of common medications on male fertility. Nat Rev Urol. 2015;12(7):401–13.
Not in our library10.1038/nrurol.2015.145
- 21.
Fusco F Franco M Longo N: The impact of non-urologic drugs on sexual function in men. Arch Ital Urol Androl. 2014;86(1):50–5.
Not in our library10.4081/aiua.2014.1.50
- 22.
Clavijo RI Carrasquillo R Ramasamy R: Varicoceles: prevalence and pathogenesis in adult men. Fertil Steril. 2017;108(3):364–9.
Not in our library10.1016/j.fertnstert.2017.06.036
- 23.
Jensen CFS Østergren P Dupree JM: Varicocele and male infertility. Nat Rev Urol. 2017;14(9):523–33.
Not in our library10.1038/nrurol.2017.98
- 24.
Cho CL Esteves SC Agarwal A: Novel insights into the pathophysiology of varicocele and its association with reactive oxygen species and sperm DNA fragmentation. Asian J Androl. 2016;18(2):186–93.
Not in our library10.4103/1008-682x.170441
- 25.
Baazeem A Belzile E Ciampi A: Varicocele and male factor infertility treatment: a new meta-analysis and review of the role of varicocele repair. Eur Urol. 2011;60(4):796–808.
Not in our library10.1016/j.eururo.2011.06.018
- 26.
Al Bakri A Lo K Grober E: Time for improvement in semen parameters after varicocelectomy. J Urol. 2012;187(1):227–31.
Not in our library10.1016/j.juro.2011.09.041
- 27.
Kirby EW Wiener LE Rajanahally S: Undergoing varicocele repair before assisted reproduction improves pregnancy rate and live birth rate in azoospermic and oligospermic men with a varicocele: a systematic review and meta-analysis. Fertil Steril. 2016;106(6):1338–43.
Not in our library10.1016/j.fertnstert.2016.07.1093
- 28.
- 29.
Esteves SC Miyaoka R Roque M: Outcome of varicocele repair in men with nonobstructive azoospermia: systematic review and meta-analysis. Asian J Androl. 2016;18(2):246–53.
Not in our library10.4103/1008-682x.169562
- 30.
Mansour Ghanaie M Asgari SA Dadrass N: Effects of varicocele repair on spontaneous first trimester miscarriage: a randomized clinical trial. Urol J. 2012;9(2):505–13.
Not in our library
- 31.
Esteves SC Sánchez-Martín F Sánchez-Martín P: Comparison of reproductive outcome in oligozoospermic men with high sperm DNA fragmentation undergoing intracytoplasmic sperm injection with ejaculated and testicular sperm. Fertil Steril. 2015;104(6):1398–405.
Not in our library10.1016/j.fertnstert.2015.08.028
- 32.
Cui X Ding P Gao G: Comparison of the Clinical Outcomes of Intracytoplasmic Sperm Injection Between Spermatozoa Retrieved From Testicular Biopsy and From Ejaculate in Cryptozoospermia Patients. Urology. 2017;102:106–10.
Not in our library10.1016/j.urology.2016.08.071
- 33.
Abhyankar N Kathrins M Niederberger C: Use of testicular versus ejaculated sperm for intracytoplasmic sperm injection among men with cryptozoospermia: a meta-analysis. Fertil Steril. 2016;105(6):1469–1475.e1.
Not in our library10.1016/j.fertnstert.2016.02.013
- 34.
Esteves SC Roque M Bradley CK: Reproductive outcomes of testicular versus ejaculated sperm for intracytoplasmic sperm injection among men with high levels of DNA fragmentation in semen: systematic review and meta-analysis. Fertil Steril. 2017;108(3):456–467.e1.
Not in our library10.1016/j.fertnstert.2017.06.018
- 35.
Spanò M Bonde JP Hjøllund HI: Sperm chromatin damage impairs human fertility. The Danish First Pregnancy Planner Study Team. Fertil Steril. 2000;73(1):43–50.
Not in our library10.1016/s0015-0282(99)00462-8
- 36.
Practice Committee of the American Society for Reproductive Medicine: The clinical utility of sperm DNA integrity testing: a guideline. Fertil Steril. 2013;99(3):673–7.
Not in our library10.1016/j.fertnstert.2012.12.049
- 37.
- 38.
Agarwal A Cho CL Majzoub A: The Society for Translational Medicine: clinical practice guidelines for sperm DNA fragmentation testing in male infertility. Transl Androl Urol. 2017;6(Suppl 4):S720–S733.
Not in our library10.21037/tau.2017.08.06
- 39.
Quinn MM Jalalian L Ribeiro S: Microfluidic sorting selects sperm for clinical use with reduced DNA damage compared to density gradient centrifugation with swim-up in split semen samples. Hum Reprod. 2018;33(8):1388–93.
Not in our library10.1093/humrep/dey239
- 40.
Ziarati N Tavalaee M Bahadorani M: Clinical outcomes of magnetic activated sperm sorting in infertile men candidate for ICSI. Hum Fertil (Camb). 2019;22(2):118–125.
Not in our library10.1080/14647273.2018.1424354
Cited by papers we hold 2
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.